Therefore, combined analysis of various predictors, such as the addition of detecting macrophage PD-L1 levels, is needed to more faithfully reflect the composition of PD-L1 in the TME, predict the efficacy of PD-1/PD-L1 blockade, and maximize the therapeutic effects of immunotherapy in patients with cancer. This evidence concerns the gene PDCD1 and cancer.